Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis

Ömür Taşkın, Taskin O, O Taskin, A I Yalcinoglu, Yalcinoglu AI, Ali İhsan Yalçinoğlu, Kucuk S, Şenol Küçük, S Kucuk, Uryan I, I Uryan, Ali Buhur, A Buhur, Burak F, F Burak, Feza Burak
Fertility and sterility · 1997 · vol. 67(1) , pp. 40–45 · doi:10.1016/s0015-0282(97)81853-5 · PMID:8986681 · W1978046639
RCT OA: bronze CC0 ⤵ 44 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study investigated the effectiveness of tibolone in treating hypoestrogenic symptoms in endometriosis patients receiving goserelin.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate the efficacy and safety of tibolone on hypoestrogenic vasomotor symptoms and bone parameters in patients treated with goserelin acetate. DESIGN: Prospective, randomized placebo controlled double-blind study. SETTING: Human volunteers in a university-based fertility clinic. PATIENT(S): Twenty-nine women of mean age 29.2 +/- 4.8 years with mild to severe endometriosis undergoing 6 months of treatment with 3.6 mg goserelin acetate in an SC depot formulation were studied. INTERVENTION(S): The patients were allocated randomly to either 2.5 mg/d tibolone (n = 15) or an iron pill (n = 14) in a double-blinded fashion beginning in the third cycle. MAIN OUTCOME MEASURE(S): Frequency and severity of hot flushes, sweating, irritability, loss of libido, nervousness, and sleeplessness were assessed by the patients using 0 to 6 point scoring system and compared. Samples of urine were obtained for calcium and creatinine (Ca:Cr) ratios at the start of treatment and monthly there after. The vasomotor scoring for each symptom and Ca:Cr ratios before the treatment and at the end of 6th month were analyzed by parametric and nonparametric tests. RESULT(S): The mean age, weight, vasomotor scores, pelvic scores, and urine Ca:Cr ratios were similar in both placebo and tibolone group (28.7 +/- 4.8 versus 27.6 +/- 6.3 years, 50.9 +/- 5.3 versus 53.1 +/- 7.1 kg, 4.7 +/- 1.1 versus 4.2 +/- 0.8, and 0.056 +/- 0.008 versus 0.059 +/- 0.006, respectively). The decreases in vasomotor scoring as regards to hot flushing, sweating, and other associated symptoms were statistically significant in tibolone group compared with placebo (10.4 +/- 1.6 versus 24.6 +/- 4.9). During the study significant reductions in urine Ca:Cr ratio was obtained in the tibolone patients compared with placebo (0.031 +/- 0.006 versus 0.0055 +/- 0.007). The incidence of side effects (weight change, vaginal bleeding) was low and did not differ from the placebo group. CONCLUSION(S): Considering the beneficial effects of tibolone on vasomotor symptoms and bone loss, our data suggest that this synthetic steroid is an effective and safe option in relieving symptoms induced by GnRH-analogue.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Anabolic Agents Endometriosis Estradiol Goserelin Norpregnenes Adult Adult Anabolic Agents Anabolic Agents Double-Blind Method Double-Blind Method Endometriosis Endometriosis Estradiol Estradiol Female Female Follicle Stimulating Hormone Follicle Stimulating Hormone Follicle Stimulating Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (44)

Source provenance

europepmc
last seen: 2026-10-12T06:17:10.165071+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T22:00:02.201502+00:00
License: CC0 · commercial use OK